Cargando…

Decoys Selection in Benchmarking Datasets: Overview and Perspectives

Virtual Screening (VS) is designed to prospectively help identifying potential hits, i.e., compounds capable of interacting with a given target and potentially modulate its activity, out of large compound collections. Among the variety of methodologies, it is crucial to select the protocol that is t...

Descripción completa

Detalles Bibliográficos
Autores principales: Réau, Manon, Langenfeld, Florent, Zagury, Jean-François, Lagarde, Nathalie, Montes, Matthieu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5787549/
https://www.ncbi.nlm.nih.gov/pubmed/29416509
http://dx.doi.org/10.3389/fphar.2018.00011
_version_ 1783295954713051136
author Réau, Manon
Langenfeld, Florent
Zagury, Jean-François
Lagarde, Nathalie
Montes, Matthieu
author_facet Réau, Manon
Langenfeld, Florent
Zagury, Jean-François
Lagarde, Nathalie
Montes, Matthieu
author_sort Réau, Manon
collection PubMed
description Virtual Screening (VS) is designed to prospectively help identifying potential hits, i.e., compounds capable of interacting with a given target and potentially modulate its activity, out of large compound collections. Among the variety of methodologies, it is crucial to select the protocol that is the most adapted to the query/target system under study and that yields the most reliable output. To this aim, the performance of VS methods is commonly evaluated and compared by computing their ability to retrieve active compounds in benchmarking datasets. The benchmarking datasets contain a subset of known active compounds together with a subset of decoys, i.e., assumed non-active molecules. The composition of both the active and the decoy compounds subsets is critical to limit the biases in the evaluation of the VS methods. In this review, we focus on the selection of decoy compounds that has considerably changed over the years, from randomly selected compounds to highly customized or experimentally validated negative compounds. We first outline the evolution of decoys selection in benchmarking databases as well as current benchmarking databases that tend to minimize the introduction of biases, and secondly, we propose recommendations for the selection and the design of benchmarking datasets.
format Online
Article
Text
id pubmed-5787549
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-57875492018-02-07 Decoys Selection in Benchmarking Datasets: Overview and Perspectives Réau, Manon Langenfeld, Florent Zagury, Jean-François Lagarde, Nathalie Montes, Matthieu Front Pharmacol Pharmacology Virtual Screening (VS) is designed to prospectively help identifying potential hits, i.e., compounds capable of interacting with a given target and potentially modulate its activity, out of large compound collections. Among the variety of methodologies, it is crucial to select the protocol that is the most adapted to the query/target system under study and that yields the most reliable output. To this aim, the performance of VS methods is commonly evaluated and compared by computing their ability to retrieve active compounds in benchmarking datasets. The benchmarking datasets contain a subset of known active compounds together with a subset of decoys, i.e., assumed non-active molecules. The composition of both the active and the decoy compounds subsets is critical to limit the biases in the evaluation of the VS methods. In this review, we focus on the selection of decoy compounds that has considerably changed over the years, from randomly selected compounds to highly customized or experimentally validated negative compounds. We first outline the evolution of decoys selection in benchmarking databases as well as current benchmarking databases that tend to minimize the introduction of biases, and secondly, we propose recommendations for the selection and the design of benchmarking datasets. Frontiers Media S.A. 2018-01-24 /pmc/articles/PMC5787549/ /pubmed/29416509 http://dx.doi.org/10.3389/fphar.2018.00011 Text en Copyright © 2018 Réau, Langenfeld, Zagury, Lagarde and Montes. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Réau, Manon
Langenfeld, Florent
Zagury, Jean-François
Lagarde, Nathalie
Montes, Matthieu
Decoys Selection in Benchmarking Datasets: Overview and Perspectives
title Decoys Selection in Benchmarking Datasets: Overview and Perspectives
title_full Decoys Selection in Benchmarking Datasets: Overview and Perspectives
title_fullStr Decoys Selection in Benchmarking Datasets: Overview and Perspectives
title_full_unstemmed Decoys Selection in Benchmarking Datasets: Overview and Perspectives
title_short Decoys Selection in Benchmarking Datasets: Overview and Perspectives
title_sort decoys selection in benchmarking datasets: overview and perspectives
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5787549/
https://www.ncbi.nlm.nih.gov/pubmed/29416509
http://dx.doi.org/10.3389/fphar.2018.00011
work_keys_str_mv AT reaumanon decoysselectioninbenchmarkingdatasetsoverviewandperspectives
AT langenfeldflorent decoysselectioninbenchmarkingdatasetsoverviewandperspectives
AT zaguryjeanfrancois decoysselectioninbenchmarkingdatasetsoverviewandperspectives
AT lagardenathalie decoysselectioninbenchmarkingdatasetsoverviewandperspectives
AT montesmatthieu decoysselectioninbenchmarkingdatasetsoverviewandperspectives